Alagille综合征
Alagille syndrome
定义 英文原文(暂无中文)
A rare developmental disease characterized by the variable association of chronic cholestasis due to paucity of intrahepatic bile ducts, congenital heart disease including pulmonary artery stenosis, butterfly-shaped vertebrae, posterior embryotoxon, characteristic facies, frequent growth retardation, glomerular/tubular kidney disease, and diffuse vascular arterial anomalies.
别名
综合征性肝胆管缺失
基本事实
- 遗传方式
- 常染色体显性
- 发病年龄
- 各年龄段
- 患病率
- 1-9 / 100 000(Europe)
相关基因 2来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| JAG1 | jagged canonical Notch ligand 1 | ORPHA:261619 |
| NOTCH2 | notch receptor 2 | ORPHA:261629 |
临床表型 43
极常见 99–80%6
- 胆汁淤积 HP:0001396
- 角膜营养不良 HP:0001131
- 发育迟滞 HP:0001508
- 肝脏肿大 HP:0002240
- 肝内胆管数量减少 HP:0006571
- 室间隔缺损 HP:0001629
常见 79–30%12
- 椎体形态异常 HP:0003312
- 蝴蝶椎弓 HP:0004617
- 面容粗糙 HP:0000280
- 前额突出 HP:0002007
- 胎儿宫内发育迟缓 HP:0001511
- 长鼻 HP:0003189
- 尖下巴 HP:0000307
- 招风耳 HP:0000411
- 圆脸 HP:0000311
- 隐性脊柱裂 HP:0003298
- 皮肤毛细血管扩张 HP:0100585
- 椎体分节缺陷 HP:0003422
偶见 29–5%25
- 瞳孔形态异常 HP:0000615
- 肋骨形态异常 HP:0000772
- 输尿管异常 HP:0000069
- 房间隔缺损 HP:0001631
- 短头畸形 HP:0000248
- 第五指屈指畸形 HP:0004209
- 隐睾 HP:0000028
- 眼睛深陷 HP:0000490
- 青春期发育延迟 HP:0000823
- 骨成熟延迟 HP:0002750
- 下斜睑裂 HP:0000494
- 扁平脸 HP:0012368
- 眼距过宽 HP:0000316
- 高血压 HP:0000822
- 尺骨发育不良 HP:0003022
- 轻度智力障碍 HP:0001256
- 圆锥角膜 HP:0000563
- 小下颌 HP:0000347
- 肾病综合征 HP:0000100
- 周围肺动脉狭窄 HP:0004969
- 肾发育不良/不全 HP:0008678
- 末节指骨短 HP:0009882
- 人中短 HP:0000322
- 特定的学习障碍 HP:0001328
- 斜视 HP:0000486
近两年的全球研究 624L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-10Abstracts
- 2026-09综述开放获取Cell differentiation-related signaling pathways: biological functions, diseases and therapeutic targets
- 2026-09Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome
- 2026-09病例报告开放获取Memantine-Induced Cholestasis and Acute Hepatitis in an 8-Week-Old Term Infant
- 2026-09Use of ileal bile acid transporter inhibitors in children with genetic familial cholestasis and Alagille syndrome: the why, when and how
- 2026-09Genetic Spectrum of Cholestasis in Tunisia and Diagnostic Yield of Next-Generation Sequencing: Case Series of 70 Patients
- 2026-09综述病例报告Phenotypic characteristics and clinical management of Alagille syndrome with multiple intracranial aneurysms: a case report and literature review
- 2026-09综述Beyond Heritable PAH: Pulmonary Hypertension in Genetic Syndromes
- 2026-09病例报告Characterization of stem cells from exfoliated deciduous teeth from a patient with Alagille syndrome carrying a JAG1 mutation
- 2026-09病例报告开放获取Severe pulmonary valve stenosis associated with advanced atrioventricular conduction disease: A rare case report
- 2026-09开放获取Stratified Use of Genetic Testing in Liver Disease Improves Diagnostic Yield and Clinical Impact
- 2026-09Triaging infantile cholestasis: Validation of non-invasive diagnostic modalities and a composite scoring system for early detection of biliary atresia
- 2026-09开放获取JAG1 c.1615C > T mutation impairs bile duct regeneration but not differentiation in hepatic organoids derived from a patient with Alagille syndrome
- 2026-09开放获取Duodenal fluid analysis of 13 patients with progressive familial intrahepatic cholestasis type 2 from a single institution
- 2026-09综述开放获取BAFF and APRIL Receptors in B Cell Immunity and Autoimmunity
- 2026-09荟萃分析系统综述Outcomes of ABO-Incompatible Versus ABO-Compatible Liver Transplantation in Pediatric Recipients: An Updated Systematic Review and Meta-Analysis
- 2026-08开放获取TargetQC: A targeted quality control framework for clinical genomic testing
- 2026-08病例报告开放获取Idiopathic Midaortic Syndrome: An Unusual Case of Acute Kidney Injury (AKI) in Secondary Hypertension With Renal Collaterals in an Adult
- 2026-08开放获取Chinese expert consensus on the treatment and diagnosis of moyamoya disease and moyamoya syndrome (2024)
- 2026-08开放获取Systematic Review of Renal Infarction Clinical Presentation, Causes, and Outcomes
境外已获批用于本病的药物 4L2
欧盟 2 项、美国 2 项。同一药物在两地各批一次的,会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。
药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。
- Livmarli欧盟2022-12-09maralixibat chloride官方记录
- Kayfanda欧盟2024-09-19odevixibat官方记录
- Livmarli美国2021-09-29maralixibat官方记录
- Bylvay美国2023-06-13odevixibat官方记录
尚未获批的在研药物(2 项)
这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 1L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
当前没有检索到登记为可入组的试验。
其他状态的试验(1 项)
- 已完成NCT05488067Atorvastatin Therapy on Xanthoma in Alagille Syndrome中国研究中心 1 个:Shanghai
中国境外的在招试验 10L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
共 10 项。
- 招募中NCT07335523Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation美国
- 招募中NCT07585097A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment法国、意大利
- 招募中NCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in Canada加拿大
- 招募中NCT06506734Dental Dyschromia and Quality of Life in Early Prolonged Hyperbilirubinemia法国
- 招募中NCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)日本
- 招募中NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)比利时、法国、德国、希腊、意大利、荷兰、葡萄牙、西班牙
- 招募中NCT06850038A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment美国
- 招募中NCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)美国
- 招募中NCT06767605Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)西班牙
- 招募中NCT01793168Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford澳大利亚、美国
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)